HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burns, J. Articles by Guerrero, F. Search for Related Content PubMed PubMed Citation Articles by Burns, J. Articles by Guerrero, F.

Human cellular immune response to copolymer I and myelin basic protein

Department of Neurology, Multiple Sclerosis Research Center of the University of Pennsylvania—Wistar Institute, Philadelphia, PA.

Copolymer I (Cop I) is being tested as a treatment for MS because it protects animals against experimental allergic encephalomyelitis, and because there is immunologic cross-reactivity reported between Cop I and myelin basic protein (MBP). From the peripheral blood mononuclear cells of four normal individuals, we isolated helper-phenotype T-cell lines that reacted in vitro with Cop I or MBP. Cop I-reactive cell lines did not respond to MBP, nor did MBP-reactive T-cell lines respond to Cop I. Antigen-specific immune tolerance was induced in MBP-reactive cell lines by exposure to MBP in vitro, but similar exposure to Cop I did not induce tolerance in the MBP-reactive cell lines. We found no evidence of immunologic cross-reactivity between Cop I and MBP.

Address correspondence and reprint requests to Dr. Burns, Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce, Philadelphia, PA 19104.

Supported by a Harry Weaver Neuroscience Scholarship Award and Grant RG 894-C-4 from the National Multiple Sclerosis Society.

Accepted for publication May 8, 1985.

This article has been cited by other articles:

				A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF]

				M Chen, B Gran, K Costello, K Johnson, R Martin, and S Dhib-Jalbut Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS Multiple Sclerosis, August 1, 2001; 7(4): 209 - 219. [Abstract] [PDF]

				O. Neuhaus, C. Farina, H. Wekerle, and R. Hohlfeld Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology, March 27, 2001; 56(6): 702 - 708. [Abstract] [Full Text] [PDF]

				B. Gran, L. R. Tranquill, M. Chen, B. Bielekova, W. Zhou, S. Dhib-Jalbut, and R. Martin Mechanisms of immunomodulation by glatiramer acetate Neurology, December 12, 2000; 55(11): 1704 - 1714. [Abstract] [Full Text] [PDF]

				Y. Ge, R. I. Grossman, J. K. Udupa, J. Fulton, C. S. Constantinescu, F. Gonzales-Scarano, J. S. Babb, L. J. Mannon, D. L. Kolson, and J. A. Cohen Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment Neurology, February 22, 2000; 54(4): 813 - 817. [Abstract] [Full Text] [PDF]

				H. L. Weiner Oral tolerance with Copolymer 1 for the treatment of multiple sclerosis PNAS, March 30, 1999; 96(7): 3333 - 3335. [Full Text] [PDF]